{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:30:48Z","timestamp":1786613448541,"version":"build-2736575974"},"reference-count":36,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In multiple sclerosis (MS), disability accrual can arise from relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA). While genetic variants associated with increased MS severity have been identified, little is known on apolipoprotein E (ApoE) gene. This study aims to investigate the impact of the ApoE \u03b54 allele (ApoE4) on disability accrual in relapsing MS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with relapsing MS, aged\n                      <jats:underline>&gt;<\/jats:underline>\n                      18 years, consecutively referred to the MS centre at the University of Florence, Italy, were recruited (n=160). Patients were classified as ApoE4 carriers and non-carriers. The first confirmed disability accrual (CDA) was defined as \u226524-week confirmed disability increase from roving baseline. PIRA was defined as a CDA with absence of relapses &lt;90 days before and &lt;30 days after the onset of disability accrual and confirmation event. The association between APOE4 and type of first CDA was assessed using multivariable Cox proportional hazard regressions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a follow-up of 12.3\u00b16.3 years, a first CDA occurred in 97 patients (60.6%). PIRA accounted for 58 (59.8%) CDA events in the whole sample and for 7 out of 18 (38.9%) CDA events in APOE4 non-carriers (p=0.045). Indeed, RAW was associated with ApoE4 in the whole sample (HR=3.33, 95% CI 1.53 to 7.27, p=0.002) and in patients with relapses during follow-up (HR=3.60, 95%\u2009CI 1.62 to 8.02, p=0.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Our study underscores the importance of genetic factors such as ApoE4 in MS pathogenesis. The identification of genetic markers associated with specific patterns of disability accrual could unveil mechanisms of damage accumulation and provide new therapeutic targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-338392","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:25:23Z","timestamp":1777569923000},"page":"774-779","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Relapse-associated worsening in apolipoprotein E \u03b54 carriers with relapsing multiple sclerosis"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-1762","authenticated-orcid":false,"given":"Emilio","family":"Portaccio","sequence":"first","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Aprea","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Neurologia, Santa Maria del Carmine Hospital of Rovereto, Rovereto, Trentino-Alto Adige\/South Tyrol, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-1111","authenticated-orcid":false,"given":"Ermelinda","family":"De Meo","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-3971","authenticated-orcid":false,"given":"Matteo","family":"Betti","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6659-0471","authenticated-orcid":false,"given":"Ilaria","family":"Addazio","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Pasto\u2019","sequence":"additional","affiliation":[{"name":"University Hospital Careggi, Florence, Tuscany, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3927-1614","authenticated-orcid":false,"given":"Chiara","family":"Ballerini","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-9040","authenticated-orcid":false,"given":"Benedetta","family":"Nacmias","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-3760","authenticated-orcid":false,"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of NEUROFARBA, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026081302150831000_97.9.774.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858"},{"key":"2026081302150831000_97.9.774.2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac111"},{"key":"2026081302150831000_97.9.774.3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026081302150831000_97.9.774.4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25463"},{"key":"2026081302150831000_97.9.774.5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026081302150831000_97.9.774.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00255-1"},{"key":"2026081302150831000_97.9.774.7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/19714009221150853","article-title":"Predictors of long-term disability in multiple sclerosis patients using routine magnetic resonance imaging data: A 15-year retrospective study","volume":"36","author":"Altokhis","year":"2023","journal-title":"Neuroradiol J"},{"key":"2026081302150831000_97.9.774.8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy088"},{"key":"2026081302150831000_97.9.774.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.263"},{"key":"2026081302150831000_97.9.774.10","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00180","article-title":"APOE and Alzheimer\u2019s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction","volume":"10","author":"Brandon","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"2026081302150831000_97.9.774.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19264-0"},{"key":"2026081302150831000_97.9.774.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.3.312"},{"key":"2026081302150831000_97.9.774.13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.57.5.853","article-title":"Apolipoprotein E \u03b54 is associated with rapid progression of multiple sclerosis","volume":"57","author":"Fazekas","year":"2001","journal-title":"Neurology"},{"key":"2026081302150831000_97.9.774.14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1600-0404.2009.01278.x","article-title":"ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis","volume":"120","author":"Portaccio","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"2026081302150831000_97.9.774.15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/01.wnl.0000210531.19498.3f","article-title":"APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers","volume":"66","author":"Burwick","year":"2006","journal-title":"Neurology"},{"key":"2026081302150831000_97.9.774.16","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509348512"},{"key":"2026081302150831000_97.9.774.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2026081302150831000_97.9.774.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"2026081302150831000_97.9.774.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2026081302150831000_97.9.774.20","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90054-X"},{"key":"2026081302150831000_97.9.774.21","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213977","article-title":"Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis","volume":"105","author":"Portaccio","year":"2025","journal-title":"Neurology"},{"key":"2026081302150831000_97.9.774.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601120"},{"key":"2026081302150831000_97.9.774.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06250-x"},{"key":"2026081302150831000_97.9.774.24","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70264","article-title":"Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis","volume":"32","author":"Clarelli","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026081302150831000_97.9.774.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.5.1977"},{"key":"2026081302150831000_97.9.774.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-023-00776-9"},{"key":"2026081302150831000_97.9.774.27","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/brain\/awab478","article-title":"APOE4 derived from astrocytes leads to blood-brain barrier impairment","volume":"145","author":"Jackson","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2026081302150831000_97.9.774.28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood\u2013brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature New Biol"},{"key":"2026081302150831000_97.9.774.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00754","article-title":"The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer\u2019s Disease","volume":"11","author":"Kloske","year":"2020","journal-title":"Front Immunol"},{"key":"2026081302150831000_97.9.774.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.01.003"},{"key":"2026081302150831000_97.9.774.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-018-0249-5","article-title":"Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury","volume":"13","author":"Main","year":"2018","journal-title":"Mol Neurodegener"},{"key":"2026081302150831000_97.9.774.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13088-7"},{"key":"2026081302150831000_97.9.774.33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","article-title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study","volume":"24","author":"Boon","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026081302150831000_97.9.774.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104795"},{"key":"2026081302150831000_97.9.774.35","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26913"},{"key":"2026081302150831000_97.9.774.36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-338392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:15:51Z","timestamp":1786612551000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-338392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,13]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jnnp-2025-338392"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-338392","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}